Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

FDA extends review period for low-dose Yasmin NDA

July 21, 2004

Xanthine derivatives under development at Sumitomo

July 20, 2004

PTP-1B inhibitors for the treatment of insulin resistance

July 20, 2004

Inhibitors of hepatic gluconeogenesis in early development at Sumitomo

July 20, 2004

Takeda discloses melanin-concentrating hormone (MCH) antagonists

July 20, 2004

I2S receives fast track status for Hunter's syndrome

July 20, 2004

Rosiglitazone improves insulin activity and affects adipose cell turnover in obese rats

July 20, 2004

Melanocortin MC4 receptor agonists described in patent literature

July 19, 2004

Promising results reported for APD-356 in the treatment of obesity

July 19, 2004

Positive phase II results for Alista in premenopausal women with FSAD

July 19, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 22, 2026.
‘Detargeted’ targeted gene therapy improves activity in Pompe
BioWorld
A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...
Roche reports new TREM2 agonists
BioWorld Science
F. Hoffmann-la Roche Ltd. and Hoffmann-La Roche Inc. have identified new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for...
Genescience presents STAT6 degrader for atopic dermatitis
BioWorld Science
Genescience Pharmaceutical Co. Ltd. has presented data on a new STAT6 PROTAC degrader – GenSciP166 – which selectively targets STAT6 for proteasomal degradation....
Unmasking the X: EPAC2 shifts the fragile X landscape
BioWorld
Researchers at UCLA have shown that divergent neuronal signaling in fragile X mice converges on EPAC2, a druggable target whose inhibition restores circuit...